Gilead Sciences Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Gilead Sciences Bundle
Unlock Strategic Clarity
Gilead Sciences' BCG Matrix offers a strategic lens to understand its product portfolio's market share and growth potential. By categorizing its offerings into Stars, Cash Cows, Dogs, and Question Marks, you can pinpoint areas of strength and opportunity.
Unlock the full potential of this analysis by purchasing the complete Gilead Sciences BCG Matrix. Gain a comprehensive breakdown of each product's quadrant placement and discover actionable insights to optimize your investment and product development strategies.
Stars
Lenacapavir (formerly Yeztugo) for HIV Prevention
Lenacapavir, potentially launching as Yeztugo for HIV prevention around mid-2025, is a strong contender for Gilead Sciences' Stars category. Its twice-yearly injection schedule offers unparalleled convenience, a significant differentiator in the HIV prevention market.
Clinical trials have demonstrated near-perfect efficacy, suggesting it could redefine prevention standards and capture substantial market share. This addresses a critical unmet need, promising robust uptake and future growth for Gilead.
Trodelvy (sacituzumab govitecan-hziy)
Trodelvy, a key oncology asset for Gilead Sciences, showcases robust performance with a 24% sales increase for the full year 2024, reaching $1.2 billion. This growth, including a 19% rise in Q4 2024, positions it as a strong contender in the competitive cancer treatment landscape.
Its established leadership in metastatic triple-negative breast cancer and HR+/HER2- metastatic breast cancer segments underscores its significant market share in these vital oncology areas. The sustained demand across all geographical regions further solidifies Trodelvy's competitive standing and market penetration.
Yescarta (axicabtagene ciloleucel)
Yescarta, a leading CAR-T cell therapy from Gilead Sciences, demonstrates robust growth. Full-year 2024 sales saw a 5% increase, with Q4 2024 sales rising by 6%, indicating sustained demand, especially in international markets.
Despite some competition within the U.S., Yescarta maintains a significant global market share in treating relapsed or refractory large B-cell lymphoma. This strong performance highlights its position in a rapidly advancing and high-growth segment of the oncology market.
Liver Disease Portfolio Growth
Gilead Sciences' liver disease portfolio, encompassing treatments for hepatitis B and D, experienced robust growth. In full year 2024, sales climbed by 9%, a trend that continued into Q4 2024 with another 9% increase. This expansion is fueled by heightened demand across a spectrum of liver conditions, underscoring Gilead's strong market presence in a therapeutic area with persistent medical requirements.
This growth trajectory highlights Gilead's substantial market share within a developing segment of the pharmaceutical market.
- Hepatitis B and D Treatments: Significant sales growth observed.
- Full Year 2024 Performance: 9% increase in sales.
- Q4 2024 Performance: Continued 9% sales growth.
- Market Position: Strong demand indicates high market share in a growing therapeutic area.
Livdelzi (seladelpar)
Livdelzi (seladelpar), a treatment for primary biliary cholangitis (PBC), is positioned as a potential star within Gilead Sciences' portfolio. In its second full quarter post-launch, Livdelzi generated $40 million in sales, signaling robust initial market reception. This strong performance is underpinned by its FDA Accelerated Approval and the expectation of European Medicines Agency (EMA) approval, addressing a significant unmet need in the PBC market.
The drug's rapid uptake and ongoing regulatory advancements suggest a high growth trajectory, with the potential to capture substantial market share. Livdelzi's ability to meet patient needs in a less-served therapeutic area is a key driver of its early success.
- Product: Livdelzi (seladelpar)
- Indication: Primary Biliary Cholangitis (PBC)
- Recent Sales: $40 million in second full quarter post-launch (2024 data).
- Market Potential: High growth due to unmet needs and regulatory approvals (FDA Accelerated Approval, anticipated EMA approval).
Gilead's Blockbusters: Growth & Innovation
Lenacapavir, with its potential mid-2025 launch for HIV prevention, is poised to be a Star for Gilead. Its unique twice-yearly injection offers convenience, a major advantage in the market. Clinical trials showing near-perfect efficacy suggest it could set new prevention standards and capture significant market share, addressing a critical unmet need.
Trodelvy has demonstrated impressive growth, with 2024 sales reaching $1.2 billion, a 24% increase year-over-year. Its established leadership in metastatic triple-negative breast cancer and HR+/HER2- metastatic breast cancer segments, coupled with sustained demand globally, solidifies its strong market position.
Yescarta, a leading CAR-T therapy, saw a 5% sales increase in full-year 2024, with Q4 sales up 6%. Despite some U.S. competition, it maintains a significant global market share in treating relapsed or refractory large B-cell lymphoma, highlighting its strength in a high-growth oncology segment.
Gilead's liver disease treatments for hepatitis B and D experienced robust growth, with sales climbing 9% in full-year 2024 and continuing that trend in Q4 2024. This expansion is driven by strong demand across various liver conditions, underscoring Gilead's substantial market share in a developing therapeutic area.
Livdelzi (seladelpar) is showing strong potential as a Star, generating $40 million in its second full quarter post-launch in 2024. Its FDA Accelerated Approval and anticipated EMA approval address a significant unmet need in primary biliary cholangitis (PBC), suggesting a high growth trajectory and substantial market share capture.
| Product | Therapeutic Area | 2024 Sales Growth | Key Market Position |
|---|---|---|---|
| Lenacapavir | HIV Prevention | Projected High Growth (Launch 2025) | Unparalleled convenience, high efficacy |
| Trodelvy | Oncology | 24% (Full Year 2024) | Leader in metastatic breast cancer |
| Yescarta | Oncology (CAR-T) | 5% (Full Year 2024) | Significant global share in B-cell lymphoma |
| Hepatitis B & D Treatments | Liver Disease | 9% (Full Year 2024) | Strong demand in growing segment |
| Livdelzi | Primary Biliary Cholangitis (PBC) | $40M (2nd Qtr Post-Launch 2024) | Addresses unmet need, high growth potential |
What is included in the product
Detailed Word Document
The Gilead Sciences BCG Matrix analyzes its product portfolio, identifying which business units to invest in, hold, or divest based on market share and growth.
Customizable Excel Spreadsheet
The Gilead Sciences BCG Matrix provides a clear, actionable roadmap for resource allocation, alleviating the pain of uncertain investment decisions.
Cash Cows
Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide)
Biktarvy stands as a cornerstone for Gilead Sciences, firmly positioned as a Cash Cow within the company's BCG Matrix. Its exceptional performance in the HIV treatment sector solidifies its status as a consistent and significant revenue generator.
With full-year 2024 sales reaching an impressive $13.4 billion, marking a 13% increase from the previous year, Biktarvy demonstrates robust market demand. This growth underscores its continued dominance in a mature yet stable therapeutic area.
Holding over 50% of the U.S. market share for HIV treatment, Biktarvy's leadership is undeniable. This strong market position translates directly into substantial and reliable cash flow for Gilead Sciences.
Descovy (emtricitabine/tenofovir alafenamide)
Descovy, a crucial medication for HIV treatment and prevention (PrEP), is a prime example of a Cash Cow for Gilead Sciences. In 2024, its sales reached $2.1 billion, marking a healthy 6% growth over the previous year. This consistent performance underscores its established position in a stable market.
With over 40% of the PrEP market share, Descovy demonstrates strong customer loyalty and a significant competitive advantage. The drug's reliable sales contribute substantial and steady cash flow to Gilead, solidifying its status as a mature, high-performing product.
Overall HIV Portfolio
Gilead's HIV portfolio is a significant cash cow, evidenced by its impressive $19.6 billion in sales for the full year 2024, marking an 8% rise compared to 2023. This robust performance highlights the segment's maturity and Gilead's dominant position within the HIV market, ensuring a consistent and substantial revenue stream.
The sustained demand and volume growth across Gilead's HIV products are clear indicators of their cash-generating capabilities. This mature segment acts as a stable financial bedrock for the company, allowing for continued investment and strategic flexibility.
Vemlidy (tenofovir alafenamide) for HBV
Vemlidy, featuring tenofovir alafenamide, is a cornerstone of Gilead Sciences' liver disease business, positioning it as a strong Cash Cow. While precise standalone sales for Vemlidy aren't always broken out in recent reports, its contribution to Gilead's overall liver disease segment, which experienced growth in 2023, is significant. This medication is a leading therapy for chronic hepatitis B, a market that, while competitive, remains relatively stable, ensuring consistent cash generation for the company.
Gilead's liver disease franchise, including Vemlidy, is a vital contributor to its financial stability. The drug's established efficacy and safety profile in treating chronic hepatitis B solidify its market position. This consistent performance allows Gilead to leverage the cash flow generated from Vemlidy to fund research and development in other areas.
- Vemlidy's Role: A key revenue driver within Gilead's liver disease portfolio.
- Market Position: A leading treatment for chronic hepatitis B, benefiting from a stable market.
- Financial Impact: Contributes consistently to Gilead's cash flow, supporting broader company investments.
- Gilead's Liver Disease Segment: Saw overall growth in 2023, underscoring the strength of its portfolio which includes Vemlidy.
Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide)
Genvoya, a cornerstone of Gilead Sciences' HIV portfolio, continues to be a significant contributor, even as newer therapies emerge. Its established position in the market ensures a stable revenue stream for the company.
While Biktarvy has taken the lead in driving growth, Genvoya remains a dependable performer in the mature HIV segment. Its consistent sales underscore its role as a reliable cash cow.
- Genvoya's Contribution: Continues to bolster Gilead's robust HIV franchise.
- Market Position: Maintains a steady presence in the mature HIV market.
- Sales Performance: Generates consistent, reliable revenue despite not being the fastest-growing product.
- Cash Generation: Acts as a dependable cash generator for Gilead Sciences.
HIV Franchise: A Billion-Dollar Cash Cow
Gilead's HIV franchise is a powerhouse, consistently generating substantial revenue and acting as a prime example of a Cash Cow. The segment's maturity, coupled with Gilead's dominant market share, ensures a reliable and significant inflow of cash for the company.
This segment's strength is highlighted by its impressive full-year 2024 sales of $19.6 billion, an 8% increase from 2023, demonstrating sustained demand and volume growth. This financial bedrock provides Gilead with the flexibility to invest in future growth opportunities.
Products like Biktarvy, with $13.4 billion in 2024 sales and over 50% of the U.S. HIV market share, and Descovy, with $2.1 billion in 2024 sales and over 40% of the PrEP market share, are key drivers of this cash cow status.
| Product | 2024 Sales (Billions USD) | Year-over-Year Growth | Market Share (U.S. HIV/PrEP) |
|---|---|---|---|
| Biktarvy | $13.4 | 13% | >50% |
| Descovy | $2.1 | 6% | >40% (PrEP) |
| Genvoya | N/A (Included in HIV Franchise) | N/A | Mature Market Presence |
| Vemlidy | N/A (Included in Liver Disease) | N/A | Leading Chronic Hep B Treatment |
| Gilead HIV Franchise Total | $19.6 | 8% | Dominant |
Preview = Final Product
Gilead Sciences BCG Matrix
The Gilead Sciences BCG Matrix preview you are viewing is the identical, fully formatted report you will receive upon purchase, ensuring immediate strategic insights without any alterations or watermarks.
This preview accurately represents the complete Gilead Sciences BCG Matrix document that will be delivered to you after your purchase, offering uncompromised data and professional analysis for your business planning.
Rest assured, the Gilead Sciences BCG Matrix you see here is precisely the file you will download after completing your purchase, providing a ready-to-use tool for evaluating your product portfolio's market position.
What you are previewing is the actual, comprehensive Gilead Sciences BCG Matrix document that will be yours to utilize immediately after purchase, enabling swift and informed strategic decision-making.
Dogs
Veklury (remdesivir)
Veklury (remdesivir), once a star product for Gilead Sciences, is now showing signs of a significant downturn. In 2024, its sales saw a substantial drop of 18% for the full year, with an even steeper decline of 53% in the fourth quarter. This sharp decrease is largely attributed to the declining rates of COVID-19 related hospitalizations, which was the primary driver for Veklury's demand.
The market for COVID-19 treatments is rapidly shrinking, and as a result, Veklury's market share within this segment is diminishing. This trend positions Veklury as a product that is no longer a significant contributor to Gilead Sciences' overall revenue, marking a clear shift in its market standing.
Tecartus (brexucabtagene autoleucel) in the U.S.
Tecartus, a CAR T-cell therapy for certain blood cancers, faces a challenging U.S. market. While global sales saw a 9% rise in 2024, U.S. demand has notably softened, with Q1 2025 sales declining by 22% year-over-year.
This downturn in the United States is attributed to heightened competition, both from therapies within the same class and those targeting similar patient populations. Such a trend suggests a weakening market position for Tecartus in the U.S. oncology segment.
Considering its declining market share in a highly competitive space, Tecartus could be classified as a 'dog' within Gilead Sciences' U.S. market portfolio, signaling a need for strategic evaluation.
Older HCV Treatments (e.g., Harvoni, Sovaldi)
Gilead's older Hepatitis C virus (HCV) treatments, like Harvoni and Sovaldi, are positioned as dogs in the BCG matrix. Their sales have been on a downward trend, primarily because the number of people needing these specific treatments is shrinking, and newer, more competitive options have emerged. This has led to a decline in patient starts and pressure on pricing, making them a low-growth, low-market-share segment within Gilead's broader liver disease portfolio.
Certain Legacy HIV Therapies
Certain legacy HIV therapies from Gilead Sciences, those predating their current TAF-based regimens, are likely positioned as Dogs in the BCG Matrix. These older medications have faced significant market share erosion due to the introduction of newer, more efficacious, and better-tolerated treatments, both from Gilead itself and from competing pharmaceutical companies. Consequently, these legacy drugs operate within a low-growth market segment, attracting minimal new investment as the company focuses resources on its more innovative offerings.
The market for older HIV treatments has seen a noticeable shift. For instance, while specific 2024 market share data for these legacy drugs is not publicly detailed in isolation, the overall HIV market continues to evolve. Gilead's own TAF-based regimens, such as Biktarvy, have become dominant, capturing substantial market share and indicating a clear preference for newer formulations. This trend underscores the competitive pressure on older therapies, pushing them into a category with limited future growth potential and reduced strategic importance.
- Low Market Share: Older HIV therapies have seen their market share decline significantly.
- Low Growth Market: The segment for these legacy drugs is characterized by minimal expansion.
- Minimal Investment: Gilead is unlikely to allocate substantial resources to these older products.
- Competitive Pressure: Newer, more advanced HIV treatments from Gilead and competitors have displaced these legacy options.
Products Facing Generic Competition
As patents on established medications expire, Gilead Sciences, like many pharmaceutical companies, faces the inevitable challenge of generic competition. This typically leads to a decline in market share and profitability for these older products. While specific drugs in this category aren't highlighted in recent public disclosures, it's understood that Gilead would have a portfolio of products in this phase.
These drugs, by their nature, are usually in a low-growth market segment. Their market share, once dominant, begins to erode as lower-cost generic alternatives become available. This dynamic is a standard part of the pharmaceutical lifecycle.
- Generic Erosion: The primary characteristic of products in this category is the significant impact of generic competition following patent expiration.
- Low Market Growth: These drugs operate in mature markets with limited expansion potential, further exacerbated by generic availability.
- Declining Market Share: As generics gain traction, the originator product's market share consistently decreases.
- Profitability Pressure: Price competition from generics directly impacts the revenue and profit margins of these older medications.
Products Facing Headwinds
Gilead Sciences' portfolio includes several products that fit the 'dog' category in the BCG matrix, characterized by low market share in low-growth markets. These are often older drugs facing intense competition or declining patient populations.
Veklury (remdesivir) sales dropped 18% in 2024, with a 53% decline in Q4, due to fewer COVID-19 hospitalizations, positioning it as a dog. Similarly, older Hepatitis C treatments like Harvoni and Sovaldi are dogs due to shrinking patient pools and newer alternatives.
Legacy HIV therapies, predating current TAF regimens, also fall into the dog quadrant. Their market share has eroded significantly against newer, more effective options, including Gilead's own Biktarvy.
Products facing generic competition post-patent expiration are inherently dogs, experiencing declining market share and profitability pressure in mature, low-growth segments.
| Product/Category | BCG Classification | Key Rationale | 2024 Performance Indicator |
|---|---|---|---|
| Veklury (remdesivir) | Dog | Declining demand due to reduced COVID-19 hospitalizations. | 18% full-year sales decline. |
| Older HCV Treatments (e.g., Harvoni, Sovaldi) | Dog | Shrinking patient population and emergence of newer treatments. | Declining sales trend. |
| Legacy HIV Therapies | Dog | Significant market share erosion by newer, improved therapies. | Low market share in a mature segment. |
| Post-Patent Expiration Products | Dog | Impact of generic competition leading to market share and profitability decline. | Eroding market share and pricing pressure. |
Question Marks
Lenacapavir for HIV Treatment (Beyond PrEP)
While lenacapavir is making waves as a potential PrEP option, its true potential lies in its long-acting treatment capabilities for individuals already living with HIV. This segment represents a significant growth opportunity for Gilead Sciences, even with its current modest market share in this specific application.
Gilead is strategically positioning lenacapavir as a key future treatment for HIV, particularly for those who have extensive treatment histories and may benefit from a novel, long-acting regimen. This focus underscores a commitment to innovation in HIV therapy beyond prevention.
The company's substantial investments in developing lenacapavir for broader treatment applications reflect a belief in its ability to capture a significant portion of this high-growth market. This aligns with Gilead's broader strategy to maintain leadership in HIV management.
Early-Stage Oncology Pipeline Assets
Gilead Sciences boasts a robust early-stage oncology pipeline, with numerous assets targeting high-growth cancer indications where the company is still establishing its market footprint. These promising candidates represent significant future potential, though they necessitate substantial research and development investment, carrying inherent risks alongside the possibility of high returns.
Non-HIV/Oncology Pipeline Expansion
Gilead Sciences is strategically venturing beyond its established HIV and oncology strongholds, targeting high-growth areas like inflammation. These new therapeutic endeavors represent classic question marks in the BCG matrix, demanding substantial investment to assess their market potential and competitive positioning. For instance, Gilead's ongoing clinical trials in immunology, aiming to address unmet needs in autoimmune diseases, highlight this expansion.
The company's commitment to these nascent areas reflects a deliberate strategy to diversify revenue streams and capture future market share. While currently holding a low market share in these expanded fields, the significant investment signals Gilead's belief in their potential to evolve into future star products. This pipeline expansion is crucial for long-term growth, especially as patent cliffs loom for some of its existing blockbuster drugs.
New Indications for Existing Oncology Drugs (e.g., Trodelvy in NSCLC)
Trodelvy’s potential expansion into non-small cell lung cancer (NSCLC) represents a significant, high-growth opportunity for Gilead Sciences. While Trodelvy is already a strong performer in other indications, entering the vast NSCLC market, where its current market share is minimal, positions it as a potential Star in the BCG matrix for this specific therapeutic area. This expansion is a classic high-risk, high-reward scenario for Gilead.
Despite a recent setback with a Phase III study miss in NSCLC, Gilead remains committed to exploring further applications for Trodelvy. This continued investment in research and development for new indications, even after a trial failure, underscores the company's belief in the drug's broader potential. Such endeavors are crucial for driving future revenue growth and maintaining a competitive edge in the oncology space.
- High Growth, Low Share: Trodelvy's entry into the large NSCLC market signifies a high-growth potential area where Gilead currently holds a low market share.
- Strategic R&D Focus: Despite a recent Phase III NSCLC study miss, Gilead's continued exploration of other potential expansions highlights a strategic focus on high-risk, high-reward opportunities.
- Market Potential: The NSCLC market is substantial, offering significant revenue upside if Trodelvy can demonstrate efficacy in this new indication.
- Portfolio Diversification: Successful expansion into NSCLC would further diversify Gilead's oncology portfolio and strengthen its position against competitors.
Acquired Pipeline Assets (e.g., from CymaBay Therapeutics)
Gilead Sciences' acquisition of CymaBay Therapeutics in late 2023, finalized in early 2024 for approximately $6.1 billion, significantly bolstered its pipeline, particularly with the addition of seladelpar, a promising treatment for primary biliary cholangitis (PBC). This move positions seladelpar as a potential star in Gilead's portfolio, operating in a growing market but currently holding a nascent market share within Gilead's broader operations.
The strategic rationale behind this acquisition aligns with placing seladelpar in the question mark category of the BCG matrix. While PBC is a significant and expanding therapeutic area, seladelpar's market penetration under Gilead is still in its early stages, necessitating substantial investment for market development and competitive positioning against established therapies.
- Pipeline Asset: Seladelpar (for Primary Biliary Cholangitis)
- Market Growth: High, driven by increasing diagnosis and awareness of PBC.
- Market Share (under Gilead): Low, reflecting its recent integration into Gilead's portfolio.
- Strategic Importance: Key investment for future revenue diversification and leadership in a growing niche.
Gilead's Strategic Bets: Inflammation & Immunology
Gilead Sciences' expansion into inflammation and immunology, exemplified by its ongoing clinical trials in autoimmune diseases, represents a strategic move into high-growth markets where its current share is minimal. These ventures are classic question marks, demanding significant investment to establish market presence and competitive footing.
The company's commitment to these nascent therapeutic areas is a deliberate strategy to diversify revenue and capture future market share, especially as patent expirations loom for some existing blockbuster drugs. This pipeline expansion is critical for long-term growth and maintaining a competitive edge.
While these areas require substantial R&D, the potential for high returns positions them as crucial question marks that could evolve into future star products for Gilead Sciences.
BCG Matrix Data Sources
Our Gilead Sciences BCG Matrix is built on verified market intelligence, combining financial data, industry research, and official reports to ensure reliable, high-impact insights.
